- Home
- INR vs DMAC Comparison
INR vs DMAC Comparison
Compare INR & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INR
- DMAC
- Stock Information
- Founded
- INR 2017
- DMAC 2000
- Country
- INR United States
- DMAC United States
- Employees
- INR N/A
- DMAC N/A
- Industry
- INR
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- INR
- DMAC Health Care
- Exchange
- INR NYSE
- DMAC Nasdaq
- Market Cap
- INR 295.3M
- DMAC 178.0M
- IPO Year
- INR 2025
- DMAC N/A
- Fundamental
- Price
- INR $15.22
- DMAC $3.78
- Analyst Decision
- INR Strong Buy
- DMAC Strong Buy
- Analyst Count
- INR 7
- DMAC 2
- Target Price
- INR $26.86
- DMAC $8.00
- AVG Volume (30 Days)
- INR 413.0K
- DMAC 310.7K
- Earning Date
- INR 08-11-2025
- DMAC 08-06-2025
- Dividend Yield
- INR N/A
- DMAC N/A
- EPS Growth
- INR N/A
- DMAC N/A
- EPS
- INR 1.89
- DMAC N/A
- Revenue
- INR $293,962,000.00
- DMAC N/A
- Revenue This Year
- INR $49.00
- DMAC N/A
- Revenue Next Year
- INR $16.39
- DMAC N/A
- P/E Ratio
- INR $8.17
- DMAC N/A
- Revenue Growth
- INR 62.18
- DMAC N/A
- 52 Week Low
- INR $13.64
- DMAC $2.90
- 52 Week High
- INR $23.00
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- INR N/A
- DMAC 48.71
- Support Level
- INR N/A
- DMAC $3.48
- Resistance Level
- INR N/A
- DMAC $3.84
- Average True Range (ATR)
- INR 0.00
- DMAC 0.27
- MACD
- INR 0.00
- DMAC 0.01
- Stochastic Oscillator
- INR 0.00
- DMAC 58.89
About INR INFINITY NATURAL RESOURCES INC
Infinity Natural Resources Inc is an oil and natural gas exploration and production company. The group focused on developing unconventional reserves in Appalachia. The company is engaged in acquiring, exploring, producing, and developing properties for producing oil, natural gas, and natural gas liquids (NGLs) from underground reservoirs.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.